



HAL
open science

Horsing Around: *Escherichia coli* ST1250 of Equine Origin Harboring Epidemic IncHI1/ST9 Plasmid with blaCTX-M-1 and an Operon for Short-Chain Fructooligosaccharide Metabolism

Adam Valcek, Petra Sismova, Kristina Nesporova, Søren Overballe-Petersen, Ibrahim Bitar, Ivana Jamborova, Arie Kant, Jaroslav Hrabak, Jaap A Wagenaar, Jean-Yves Madec, et al.

► To cite this version:

Adam Valcek, Petra Sismova, Kristina Nesporova, Søren Overballe-Petersen, Ibrahim Bitar, et al.. Horsing Around: *Escherichia coli* ST1250 of Equine Origin Harboring Epidemic IncHI1/ST9 Plasmid with blaCTX-M-1 and an Operon for Short-Chain Fructooligosaccharide Metabolism. *Antimicrobial Agents and Chemotherapy*, 2021, 65 (5), pp.e02556-20. 10.1128/aac.02556-20 . anses-04018265

HAL Id: anses-04018265

<https://anses.hal.science/anses-04018265>

Submitted on 7 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Horsing Around: *Escherichia coli* ST1250 of Equine Origin Harboring Epidemic IncHI1/ST9 Plasmid with *bla*_{CTX-M-1} and an Operon for Short-Chain Fructooligosaccharide Metabolism

Adam Valcek,^{a,b} Petra Sismova,^{a,b} Kristina Nesporova,^{a,b} Søren Overballe-Petersen,^c Ibrahim Bitar,^{d,e} Ivana Jamborova,^a Arie Kant,^f Jaroslav Hrabak,^{d,e} Jaap A. Wagenaar,^{f,k} Jean-Yves Madec,^g Peter Damborg,^h Engeline van Duijkeren,ⁱ Christa Ewers,^j Joost Hordijk,^{k*} Henrik Hasman,^c Michael S. M. Brouwer,^f Monika Dolejska^{a,b}

^aCEITEC VFU, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic

^bDepartment of Biology and Wildlife Diseases, Faculty of Veterinary Hygiene, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic

^cDepartment of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark

^dDepartment of Microbiology, Faculty of Medicine, and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic

^eBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic

^fDepartment of Bacteriology and Epidemiology, Wageningen Bioveterinary Research, Lelystad, The Netherlands

^gUniversité de Lyon–ANSES, Unité Antibiorésistance et Virulence Bactériennes, Lyon, France

^hDepartment of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark

ⁱCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands

^jInstitute of Hygiene and Infectious Diseases of Animals, Justus-Liebig-University Giessen, Giessen, Germany

^kDepartment of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands

ABSTRACT The relatedness of the equine-associated *Escherichia coli* strain ST1250 and its single- and double-locus variants (ST1250-SLV/DLV), obtained from horses in Europe, was studied by comparative genome analysis. A total of 54 isolates of *E. coli* ST1250 and ST1250-SLV/DLV from healthy and hospitalized horses across Europe (Czech Republic [$n=23$], The Netherlands [$n=18$], Germany [$n=9$], Denmark [$n=3$], and France [$n=1$]) from 2008 to 2017 were subjected to whole-genome sequencing. An additional 25 draft genome assemblies of *E. coli* ST1250 and ST1250-SLV/DLV were obtained from the public databases. The isolates were compared for genomic features, virulence genes, clade structure, and plasmid content. The complete nucleotide sequences of eight IncHI1/ST9 plasmids and one IncHI1/ST2 plasmid were obtained using long-read sequencing by PacBio or MinION. In the collection of 79 isolates, only 10 were phylogenetically close (<8 single nucleotide polymorphisms [SNP]). The majority of isolates belonged to phylogroup B1 (73/79 [92.4%]) and carried *bla*_{CTX-M-1} (58/79 [73.4%]). The plasmid content of the isolates was dominated by IncHI1 of ST9 (56/62 [90.3%]) and ST2 (6/62 [9.7%]), while 84.5% (49/58) of the *bla*_{CTX-M-1} genes were associated with the presence of the IncHI1 replicon of ST9 and 6.9% (4/58) with the IncHI1 replicon of ST2 within the corresponding isolates. The operon for the utilization of short-chain fructooligosaccharides (the *fos* operon) was present in 55 of 79 (69.6%) isolates, and all of these carried IncHI1/ST9 plasmids. The eight complete IncHI1/ST9 plasmid sequences showed the presence of *bla*_{CTX-M-1} and the *fos* operon within the same molecule. Sequences of IncHI1/ST9 plasmids were highly conserved (>98% similarity) regardless of country of origin and differed only in the structure and integration site of the multidrug resistance (MDR) region. *E. coli* ST1250 and ST1250-SLV/DLV are phylogenetically diverse strains associated with horses. A strong linkage of *E. coli* ST1250 with the epidemic multidrug resistance plasmid lineage IncHI1/ST9 carrying *bla*_{CTX-M-1} and the *fos* operon was identified.

KEYWORDS *Escherichia coli*, IncHI1, ST1250, horses, multidrug resistance, plasmids

Citation Valcek A, Sismova P, Nesporova K, Overballe-Petersen S, Bitar I, Jamborova I, Kant A, Hrabak J, Wagenaar JA, Madec J-Y, Damborg P, van Duijkeren E, Ewers C, Hordijk J, Hasman H, Brouwer MSM, Dolejska M. 2021. Horsing around: *Escherichia coli* ST1250 of equine origin harboring epidemic IncHI1/ST9 plasmid with *bla*_{CTX-M-1} and an operon for short-chain fructooligosaccharide metabolism. *Antimicrob Agents Chemother* 65:e02556-20. <https://doi.org/10.1128/AAC.02556-20>.

Copyright © 2021 American Society for Microbiology. All Rights Reserved.

Address correspondence to Monika Dolejska, monika.dolejska@gmail.com.

* Present address: Joost Hordijk, Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

Received 9 December 2020

Returned for modification 14 January 2021

Accepted 18 February 2021

Accepted manuscript posted online

22 February 2021

Published 19 April 2021

Extended-spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae*, such as ESBL-producing *Escherichia coli* (ESBL-PEC), are widespread in humans, food-producing and companion animals, wildlife, and the environment (1). ESBLs can be encoded by a variety of genes, among which the *bla*_{CTX-M} gene family dominates. The spread of *bla*_{CTX-M} in ESBL-PEC is facilitated by mobile genetic elements, including multidrug resistance (MDR) plasmids of various incompatibility (Inc) groups (2, 3).

Antimicrobial resistance is of concern for a wide range of equine pathogens. ESBL-producing *Enterobacteriaceae* have been increasingly isolated from wounds, as well as from individuals with respiratory and urinary tract infections (4). Several studies have reported the occurrence of CTX-M-1-producing *E. coli* in hospitalized but also nonhospitalized horses in many European countries, such as the Czech Republic (5, 6), Denmark (7, 8), The Netherlands (9, 10), the United Kingdom (11), Germany (12, 13), Sweden (14), Switzerland, and France (14), including Guadeloupe (15).

An epidemic IncHI1/ST9 plasmid lineage conferring multidrug resistance and harboring *bla*_{CTX-M-1} has been identified in *E. coli* isolates from hospitalized horses in the Czech Republic (5) and later in isolates from healthy and diseased horses in France (16), Sweden (14), and The Netherlands (10). Moreover, the *fos* operon, consisting of seven genes (*fosK*, *fosY*, *fosGH2*, *fosX*, *fosGH1*, *fosT*, *fosR*) involved in the metabolism of short-chain fructooligosaccharides (scFOS), has been detected on pEQ1, a conjugative IncHI1/ST9 plasmid obtained from *E. coli* T23, originating from the feces of a hospitalized horse in the Czech Republic (6). The importance of the presence of the *fos* operon arises from the fact that until Schouler et al. (17) detected the *fos* operon in extraintestinal pathogenic *E. coli*, the *fos* operon occurred only in probiotic, not pathogenic, bacteria and only as part of a chromosomally encoded genomic island. However, none of the studies mentioned above, except for that of Dolejska et al. (6), characterize the complete sequence of an epidemic IncHI1/ST9 plasmid. The presence of the *fos* operon might play a role in the coselection of multiresistance plasmids, since it provides bacteria with a metabolic advantage and enables them to grow in environments where pathogenic bacteria would normally not survive. The association of the *bla*_{CTX-M-1} gene and the *fos* operon on plasmids is particularly worrying because of the specific role of fructooligosaccharides in the horse diet and the ability of plasmids to be transferred horizontally. scFOS are commonly used prebiotics, and they are often part of a supplementary horse diet which should support gut health and beneficial microflora in horses (18). However, our results indicate that using scFOS in a horse diet may contribute to the spread of antibiotic resistance genes, so it is doubtful whether scFOS are indeed beneficial. Moreover, the use of scFOS as prebiotics is not limited to horses; they are part of many human probiotics and nutritional supplements for newborns. Therefore, more attention should be paid to the relation between the ability to utilize scFOS and antibiotic resistance.

In the current study and publicly available sequence data, *E. coli* ST1250 is found to be a rare sequence type (ST) in hosts other than horses. Moreover, the close association of *E. coli* ST1250 with IncHI1/ST9 has been observed (10, 14, 16). Clinical and nonclinical isolates of *E. coli* ST1250 and its single- and double-locus variants (ST1250-SLV/DLV) collected from horses in the Czech Republic, The Netherlands, Denmark, France, and Germany were subjected to short-read DNA sequencing. *E. coli* ST1250 was selected due to its frequent occurrence in horse samples. Other STs included are single- or double-locus variants of ST1250 and were selected both for their close relationship (with regard to the multilocus sequence type [MLST]) to ST1250 and for their frequent occurrence in horse samples. For the selected isolates, long-read sequencing was applied to obtain complete nucleotide sequences of chromosomes and IncHI1 plasmids. Additional sequences of *E. coli* ST1250 and ST1250-SLV/DLV were recovered from EnteroBase before genomic features, clade structure, and plasmid content were examined by detailed phylogenetics. Our hypothesis is that *E. coli* ST1250 is adapted to horses and has low pathogenic potential itself, while this study shows frequent

association of *E. coli* ST1250 with HI1/ST9 multiresistance plasmids encoding *bla*_{CTX-M-1} and the *fos* operon.

(This work was partially presented at the One Health European Joint Program Annual Meeting, Prague, Czech Republic, 27 to 29 May 2020 [online], in the poster section [P 153].)

RESULTS AND DISCUSSION

Genomic characterization of the isolates. A total of 79 draft genomes of *E. coli* ST1250 or ST1250-SLV/DLV, consisting of 54 sequences obtained in this study and 25 retrieved from Enterobase or GenBank, were analyzed. The majority of isolates belonged to phylogroup B1 (73/79 [92.4%]), followed by phylogroups A (5/79 [6.3%]) and E (1/79 [1.2%]). Since the collection studied was aimed at *E. coli* ST1250 and ST1250-SLV/DLV, the majority of the isolates in the collection indeed belonged to ST1250 (60/79 [75.9%]), followed by ST1250-SLV/DLV: DLV-ST4164 (4/79 [5.0%]), SLV-ST826 (3/79 [3.3%]), SLV-ST4527 (2/79 [2.5%]), SLV-ST1686 (2/79 [2.5%]), SLV-ST11123 (2/79 [2.5%]), and SLV-ST2336, SLV-ST4552, SLV-ST7434, DLV-ST11033, SLV-ST11121, and SLV-ST11122 (1/79 [1.2%] each). The common detection of *E. coli* ST1250, along with ST1250-SLV/DLV, in horses as opposed to other sources suggests that this ST is horse associated. This assumption is supported by our unpublished study of hospitalized and healthy horses across the Czech Republic, where 31.7% (20/63) of *E. coli* isolates belonged to ST1250 (6/63 [9.5%]) or ST1250-SLV/DLV (14/63 [22.2%]). Similarly, in a nationwide study conducted on nonhospitalized horses from The Netherlands (10), the most prevalent group of isolates whose whole genomes had been sequenced belonged to ST1250 (8/48 [16.7%]) or ST1250-SLV/DLV (9/48 [18.8%]). Isolates from both the Czech Republic (unpublished data) and The Netherlands are included in this study. Despite the limited number of publicly available draft genome assemblies of *E. coli* ST1250, the association of *E. coli* ST1250 with horses (7/10 [70%]) was observed in Enterobase as well, where only 1 of 10 ST1250 isolates was of human origin, while 2 were of undefined origin.

Antibiotic susceptibility testing of the isolates that were physically available ($n = 54$) showed that all exhibited a multidrug (≥ 3 antibiotics) resistance profile corresponding to a resistance genotype, except for one (d16-1) that was resistant to ciprofloxacin but susceptible to nalidixic acid, yet no *qnr* gene was detected. Among the 79 sequences analyzed for antibiotic resistance gene (ARG) content, the most prevalent ESBL genes included *bla*_{CTX-M-1} (58/79 [73.4%]), *bla*_{CTX-M-2} (6/79 [7.6%]), and *bla*_{SHV-12} (7/79 [8.9%]). While 4 isolates carried both *bla*_{CTX-M-1} and *bla*_{SHV-12}, 12 isolates did not encode any ESBL. The whole-genome sequence (WGS) data from 79 isolates showed the presence of genes conferring resistance to tetracycline, trimethoprim, sulfonamides, gentamicin, streptomycin, and chloramphenicol (see Fig. S1 in the supplemental material). Neither the resistance profile nor the plasmid content was influenced by the source of isolation (feces or clinical material). A complete profile of ARGs, along with the results of antibiotic susceptibility testing, can be found in Fig. S1.

Analysis of virulence genes showed the presence of the siderophore synthase-encoding operon *ent* and the enterobactin export-encoding gene *fes* in all 79 isolates and the enterobactin uptake-encoding operon *fep* in 75 (94.9%) isolates. These genes are common for the majority of Gram-negative bacteria (19) and may be considered beneficial for the animal hosting the bacteria carrying these genes. This has been observed in *Caenorhabditis elegans*, where the bacterial enterobactin promoted the growth of *C. elegans* via mitochondrial iron uptake (20). More than half of the isolates (56/79 [70.9%]) harbored the *fli* operon, which is involved in the biosynthesis and functioning of the flagellar organelle (21). Twelve of the 79 isolates (15.2%) carried a *fim* operon, encoding type I fimbriae. The results of *in silico* screening for virulence genes suggest that the isolates did not carry any virulence factors enabling their classification into *E. coli* pathotypes. These findings support the observation that *E. coli* ST1250 and related STs are part of the commensal equine microbiota (10).

Regarding the plasmid content, the most common plasmid replicons among the collection of 79 isolates were three IncHI1-related replicons (62/79 [78.5%]) of ST9 (56/62 [90.3%]) and ST2 (6/62 [9.7%]). The high prevalence of conjugative IncHI1/ST9 and its association with *bla*_{CTX-M-1} have been reported recently (16). IncHI1/ST9 appears to be very well adapted to *E. coli* in horses, especially *E. coli* ST1250.

Comparison of *E. coli* ST1250 and *E. coli* K-12 chromosomes. The results revealed that unlike *E. coli* K-12, the majority of *E. coli* ST1250 and ST1250-SLV/DLV strains did not carry genes encoding products facilitating adhesion and colonization (*yadN*, *ygiL*, *paa*, *yde*) (22, 23), a type II secretion pathway (*gspCO*) (24, 25), the stress response (*ygfK*, *yqeK*, *ydfO*) (26–28), short-chain fatty acid and xanthosine metabolism (*ato*, *xapA*) (29, 30), or a toxin-antitoxin system (*rnlAB*) (31). This finding suggests that *E. coli* ST1250 does not contain many virulence genes and represents a lineage with low pathogenicity that is adapted to the horse gut. Generally, in terms of genetic features that are conserved and specific for *E. coli* ST1250, no *per se* pathogenic genes were detected in the genome.

High diversity of ST1250 and ST1250-SLV/DLV. Phylogenetic analysis based on the core genome from whole-genome sequences of 79 isolates showed high diversity of *E. coli* ST1250 and ST1250-SLV/DLV (Fig. 1; also Fig. S1). The core genome alignment was created from 2,556 core genes and had a length of 3,382,416 bp. The isolates differed in 0 to 10,490 single nucleotide polymorphisms (SNP), with 10 phylogenetically close isolates differing in only 0 to 8 SNP.

The isolates in the minimum spanning tree were clustered regardless of their geographical origin and the carriage of IncHI1 plasmids (Fig. S2). Despite the high variability, three noteworthy clusters with one subcluster, marked A, BI, BII, and C, emerged (Fig. 1). Cluster A consisted of six ST1250-SLV/DLV isolates, including ST4164 (four isolates) and ST4527 (two isolates), from The Netherlands, the Czech Republic, and Germany. Their SNP differences ranged from 29 to 321, while the lowest SNP difference (29 SNP) was between a Dutch and a German isolate (15S04665-1 and IHIT_19665). Cluster B was made of subclusters BI and BII, consisting of three and four Czech ST1250 isolates with SNP differences of 1 to 16 and 0 to 8, respectively. Cluster C consisted of nine ST1250 isolates and one novel SLV. The isolates in this cluster differed in 0 to 530 SNP and originated from Switzerland, The Netherlands, the Czech Republic, Denmark, and Germany. However, presumed clonal spread of some isolates occurred only sporadically, usually within the same country. For example, no SNP differences in cluster C were observed between two couples of Swiss isolates (ESC_JA8778AA with ESC_ZA2274AA and ESC_JA8764AA with ESC_ZA2276AA).

Our findings suggest that even though there are clusters (A and C) of closely related international isolates, the isolates in these clusters belonged to several different serotypes (Fig. 1), and no clonal spread (<10 SNP) of *E. coli* ST1250 was demonstrated. Closely related isolates were observed only within subclusters BI and BII, which consist largely of isolates from the same country, sampling site, and year. Subcluster BI consisted of three isolates obtained within the same horseback riding center in 2015. Subcluster BII consisted of four isolates, of which three were obtained from a horse clinic in 2008 and one (isolate 97989) from a horseback riding center in 2015. Isolate 97989 was closely related (8 SNP) to the three isolates obtained from the horseback riding center. However, it is not clear whether this relatedness is caused by the persistence of the clone within the sampling sites over several years or by repeated introduction of the clone to the horse outside the hospital.

Phylogenetic analysis of our international collection of *E. coli* ST1250 isolates, including ST1250-SLV/DLV, indicates that *E. coli* ST1250 is genetically highly variable yet apparently associated with horses, since to our knowledge, this ST was not commonly detected in nonequine studies. However, there is no evidence of transmission of ESBL-PEc ST1250 to humans, except for one record of *E. coli* ST1250 of human origin in Enterobase, with no further information. Moreover, *E. coli* ST1250-SLV/DLV are closely related to *E. coli* ST1250 clonal lineages, highlighting the importance of whole-

Tree scale: 0.0001




FIG 1 Phylogenetic tree depicting the diversity of *E. coli* ST1250 and ST1250-SLV/DLV isolates with highlighted clusters A, B, BI, BII, and C. Isolates marked *M or *PB were sequenced on MinION or PacBio, respectively. Metadata for country of origin, year of isolation, source, ST, phylogroup, and serotype are included. Colored boxes indicate the presence of the IncH11 plasmid and its ST, the *fos* operon, and ESBL genes. The designations of physically obtained isolates are set in boldface, and data sets from EnteroBase start with "ESC." N/A, not available; E, equine; Env, equine clinic environment; H, human; NT, not typeable; NL, The Netherlands; DK, Denmark; CZ, Czech Republic; DE, Germany; CH, Switzerland; US, United States; GP, Guadeloupe; FR, France; CA, Canada.

genome sequencing and analyses based on the core genome rather than conventional 7-allele MLST profiling.

Comparative genomics of IncHI1 plasmids. IncHI1 plasmids were identified in the genomes of 62 *E. coli* strains in this study. Comparison of draft genomes and complete IncHI1 plasmids revealed two lineages of IncHI1: ST2 (6/62 [9.7%]) and ST9 (56/62 [90.3%]). These lineages are distinguished by one SNP in *repHIA* (allele HCM1_064), plasmid nucleotide identity (between p10068 [IncHI1/ST2] and p99063 [IncHI1/ST9]) of >99.9%, and >96% query coverage. They differ in the structure of the multidrug resistance (MDR) region and by the presence of the *fos* operon in IncHI1/ST9 plasmids. Once these regions were removed, comparison of the plasmid backbones of p10068 and p99063 showed nucleotide identity and query coverage of 99.98% and 99%, respectively.

The majority (45/56 [80.4%]) of isolates with IncHI1/ST9 plasmids harbored a class 1 integron with a *dfrA17-aadA5* gene cassette. Isolates carrying IncHI1/ST2 plasmids (5/6 [83.3%]) were associated with a class 1 integron with a *dfrA12-aadA2* cassette array. The other genetic features of the isolates harboring IncHI1/ST2 and IncHI1/ST9 plasmids are described in the figures presented below and in the supplemental materials. Eight complete nucleotide sequences of IncHI1/ST9 were obtained using PacBio ($n=4$) and MinION ($n=4$) long-read sequencing. Overall, they exhibited high nucleotide identities (>98%) to pEQ1 and to each other. Figure 2 shows a comparison of complete and draft genome assemblies of IncHI1/ST9 plasmids. Two different variants of the integration of an MDR region were identified within the eight complete plasmid sequences. Five plasmids harbored an MDR region of 41,754 bp (p15S04714-1) to 49,700 bp (p15S0829-4) between genes encoding a hypothetical protein of the backbone (Fig. 3, p15S04714-1). The very same position of the MDR region is found in pEQ1, of equine origin, and pHCM1 (GenBank accession no. [AL513383](https://www.ncbi.nlm.nih.gov/nuccore/AL513383)), of human origin, designated a type 2 IncHI1 plasmid based on integration sites of the MDR region inside the plasmid backbone (32). The other three plasmids contained an MDR region divided into two parts (14,708 bp and 34,143 bp) by a part of the inverted plasmid backbone of 14,228 bp (Fig. 3, p99063). This inversion was presumably mediated by two copies of IS26 flanking the backbone part (14,228 bp) and the larger, 34,143-bp part of the MDR region. This finding points to the existence of two variants of highly conserved epidemic IncHI1/ST9 plasmids differing in genetic structure, length, and the integration site of the MDR region. Besides *bla*_{CTX-M-15}, each of the eight complete IncHI1/ST9 plasmids carried genes encoding resistance to tetracycline [*tet*(B)], trimethoprim (*dfrA17*), gentamicin [*aac*(3)-*Ild*], sulfonamides (*sul1*, *sul2*), and streptomycin [*aph*(6)-*Id*, *aph*(3')-*Ib*, *aadA5*] in the MDR region. However, they differed in the presence of the *mph*(A), *aph*(3')-*Ia*, *catA1*, and *bla*_{TEM-1} genes. A Mauve comparison of the MDR region variants and their rearrangements is shown in Fig. S3. The *mer* operon, *qacEΔ1* gene, and *chrA* gene, encoding determinants for resistance to mercury, quaternary ammonium compounds, and chromium, respectively, were present in each complete IncHI1/ST9 plasmid, too (Fig. 2).

The MDR region of the complete IncHI1/ST2 plasmid obtained using MinION (p10068) was integrated between genes encoding a hypothetical protein of the backbone, identical to the integration site in IncHI1/ST9 type 2 plasmids. Unlike IncHI1/ST9 plasmids, IncHI1/ST2 plasmids did not harbor the *fos* operon. Since only one complete IncHI1/ST2 plasmid was obtained, the identity of p10068 could not be properly assessed in comparison with the draft genome assemblies from other IncHI1/ST2 plasmids ($n=5$) in this study. However, a BLAST Ring Image Generator (BRIG) comparison of p10068 with the draft genome assemblies of the other five IncHI1/ST2 plasmids (Fig. S4) showed low variability in the backbone and the MDR region of IncHI1/ST2 plasmids from the Czech Republic, Canada, and Switzerland, pointing toward the geographically widespread potential of the IncHI1/ST2 plasmid lineage. Plasmid p10068 harbored the *bla*_{CTX-M-15}, *tet*(B), *sul1*, *sul2*, *aac*(3)-*Ild*, *aadA2*, *dfrA12*, *aph*(6)-*Id*, and *aph*(3')-*Ib* genes within the 40,759-bp MDR region.




FIG 2 BRIG comparison of IncHI1/ST9 plasmids including draft genome assemblies with pEQ1 as a reference. The *fos* operon and the *bla*_{CTX-M-1} gene are annotated in red. The origins of the samples are color-coded as follows: light blue, Czech Republic; yellow, Denmark; light green and dark green, The Netherlands (different studies); dark blue, France; purple; Germany; turquoise, Switzerland.

Even though IncHI1/ST9 and IncHI1/ST2 plasmids have highly conserved backbones and differ mostly within the MDR region, IncHI1/ST2 plasmids did not harbor the *fos* operon. A higher prevalence of IncHI1/ST2 over IncHI1/ST9 has been observed only in Swedish isolates so far (14); however, no data on the presence of the *fos* operon are available from that study. In summary, comparison of IncHI1/ST9 plasmids of various geographical origins showed a highly conserved structure and high nucleotide identity, highlighting the epidemic potential of IncHI1/ST9 plasmids. Similarly, plasmid lineage Inc11-ly, harboring Ambler class A and C genes from *E. coli* and *Salmonella enterica* of animal and human origins, has been found to be epidemic (33), and IncX3 plasmids encoding NDM-type enzymes within different enterobacterial species (34) or specific NDM-5-encoding IncX3 plasmids from *E. coli* strains of diverse sequence types have been obtained from five different pig farms from different geographical regions of China (35).

The *fos* operon is highly diffused among ST1250 strains and is carried by IncHI1/ST9 plasmids. The collection of 79 *E. coli* ST1250 and ST1250-SLV/DLV isolates was screened *in silico* for the presence of the 8,896-bp *fos* operon, which is involved in the metabolism of scFOS. Fifty-eight (58/79 [73.4%]) isolates harbored the *fos* operon,




FIG 3 Comparison of two variants of the MDR regions occurring in the IncHI1/ST9 plasmids that were studied. Diagrams of two representative plasmids are shown: p15504714-1 (top) and p99063 (bottom). Plasmid backbone gene products are shown in blue, antimicrobial resistance gene products in red, transposases in orange, and hypothetical proteins (HP) in gray, unless they are part of the backbone (blue). An asterisk at an insertion sequence (IS) indicates <100% nucleotide identity with the reference IS.

while 1 isolate (ESC_ZA2274AA_AS) lacked the *fosK* gene, suggesting the presence of a nonfunctional operon. The majority (56/58 [96.6%]) of isolates harboring the *fos* operon also harbored an IncHI1/ST9 plasmid. A BRIG comparison including all IncHI1/ST9 draft genome assemblies from short-read sequencing data ($n = 56$) showed that the *fos* operon is highly conserved and is carried by this plasmid lineage (Fig. 2). The association of the *fos* operon with IncHI1/ST9 plasmids was first observed in equine isolates from the Czech Republic (6) and subsequently in The Netherlands (10) and France (16).

The broader genetic surrounding of the *fos* operon was examined within eight complete IncHI1/ST9 plasmids obtained using long-read sequencing. In all plasmids, the *fos* operon was conserved with 100% identity and surrounded by *IS903B*. As observed previously in pEQ1, the operon was part of a 24-kb module inserted between the *repE* (FIA replicon) and *hns* genes of the plasmid backbone (6). Only one of eight plasmids (p15504779-4) differed within the 24-kb module; it harbored *IS1203* upstream of the *fos* operon.

Although the association of the *fos* operon and the IncHI1/ST9 plasmid was evident, the *fos* operons of two *E. coli* ST1250 isolates (99783-3RV and T20) had different genetic contexts. Analysis of the genetic surroundings of the *fos* operon of the 99783-3RV isolate showed the presence of an IncFIB(K) replicon on the same contig, suggesting the carriage of the *fos* operon by plasmids other than IncHI1/ST9 plasmids. The limited information provided by the short-read sequencing did not enable us to identify the genetic context of the *fos* operon within the T20 strain. However, plasmid replicons IncFIB(K) and IncY were identified in T20, suggesting the possibility that the *fos* operon is either mediated by plasmid types other than IncHI1/ST9, as in the 99783-3RV isolate, or chromosomally encoded, as observed previously for *E. coli* BEN2908 (GenBank accession no. AY857617) (36).

It has been suggested that a plasmid-mediated sugar metabolic element, such as the *fos* operon, could play a key role in strain fitness, contributing to the successful dissemination and maintenance of the *fos* operon-containing MDR IncHI1/ST9 plasmids in the equine intestinal microbiota (6). We suppose that the absence of the *fos* operon in IncHI1/ST2 plasmids might contribute to their generally low prevalence, in contrast to IncHI1/ST9 plasmids, among equine *E. coli* isolates, as observed in our study, since the *fos* operon seems to provide isolates with a selective advantage in the presence of scFOS. The equine diet is usually rich in scFOS, which may, along with the usage of antibiotics, provide positive selective pressure for bacteria carrying this *fos* operon-associated plasmid lineage. However, the question of whether factors such as different amounts of scFOS in the horse feed or the geographical origin of the isolate are influencing the selection of the IncHI1/ST9 plasmid lineage needs to be clarified by further studies.

Interestingly, the presence of the *fos* operon in *E. coli* BEN2908 was linked to an increased ability to colonize the avian intestine (17). We hypothesize that the widespread

presence of the *fos* operon in *E. coli* ST1250 and ST1250-SLV/DLV isolates, as observed in our study, may compensate for the absence of known chromosomally encoded colonization factors in these strains. Further elucidation of the role of the *fos* operon in the colonization of the horse intestine by *E. coli* ST1250 would require *in vivo* experiments.

The genomic study of *E. coli* ST1250 and ST1250-SLV/DLV isolates of equine origin has shown great chromosomal diversity, which could not be linked to specific geographic regions. In comparison, the highly prevalent ESBL-encoding IncHI1/ST9 plasmids in these strains show little diversity beyond the presence of specific MDR regions and the *fos* operon. To summarize, *E. coli* ST1250 and *E. coli* ST1250-SLV/DLV isolates seem to be well adapted to horses as hosts, and *E. coli* ST1250 in particular often shows an association with IncHI1/ST9 multiresistance plasmids encoding CTX-M-type enzymes and harboring the *fos* operon, which may contribute to the coselection of these plasmids.

MATERIALS AND METHODS

***E. coli* isolates.** A total of 54 ST1250 and ST1250-SLV/DLV isolates from healthy and hospitalized horses in several countries across Europe from 2008 to 2017 were collected (Fig. S1 in the supplemental material, isolates in boldface). The isolates originated from the Czech Republic ($n=23$) (5; unpublished data), The Netherlands ($n=18$) (9), Germany ($n=9$), Denmark ($n=3$) (7), and France ($n=1$) (14). Forty-two and 12 isolates were obtained by selective cultivation on MacConkey agar (MCA) with cefotaxime (1 or 2 mg/liter) and on MCA without antibiotics, respectively. The complete details regarding processing of the samples can be found in the corresponding studies mentioned above. The majority of the isolates originated from feces (42/54), various clinical materials (10/54), and environmental swabs (2/54) (Fig. S1). Susceptibility to 22 antibiotics (ampicillin [AMP], streptomycin [S], sulfonamides [S3], tetracycline [TE], trimethoprim-sulfamethoxazole [SXT], C chloramphenicol [C], ceftazolin [KZ], nalidixic acid [NA], ceftazidime [CAZ], gentamicin [CN], amoxicillin-clavulanic acid [AMC], ciprofloxacin [CIP], fosfomycin [FOT], ertapenem [ETP], imipenem [IMP], meropenem [MEM], aztreonam [ATM], nitrofurantoin [F], azithromycin [AZM], colistin [TC], tigecycline [TGC], cephalothin [KF]) was tested by disk diffusion according to the CLSI (37), and the ESBL phenotype was determined by the MASTDISCS test (D68C1 AmpC & ESBL detection set; Mast Diagnostics, UK).

Short-read sequencing. All isolates were subjected to whole-genome sequencing (WGS) with at least 50× expected coverage. Genomic DNA was extracted using the NucleoSpin Tissue kit (Macherey-Nagel, Germany) and was used for DNA library preparation with a Nextera XT Library Preparation kit. Sequencing was performed on a MiSeq system (Illumina) using 2 × 250-bp paired-end sequencing.

Publicly available data. We searched Enterobase (<http://enterobase.warwick.ac.uk/species/index/ecoli>) for sequence data for *E. coli* ST1250 and ST1250-SLV/DLV, and assemblies along with corresponding metadata were downloaded. Available data sets for ST1250 isolates irrespective of the plasmid content and ST1250-SLV/DLV variants harboring IncHI1 were selected. Thirteen draft genome assemblies originating in Switzerland ($n=7$), Germany ($n=2$), Canada ($n=1$), the United States ($n=1$), and unknown origin ($n=2$) were retrieved from Enterobase. Additional ST1250 and ST1250-SLV/DLV sequences from horses in The Netherlands ($n=11$) and Guadeloupe ($n=1$) were retrieved from BioProject (record numbers [PRJEB34847](#) [10] and [PRJNA388339](#) [15], respectively). In total, 25 draft genome assemblies of *E. coli* ST1250 and ST1250-SLV/DLV isolates were obtained from the public databases; among these, 22 originated from horses, 2 were of unknown origin, and 1 isolate was of human origin (Fig. S1).

Long-read sequencing. PacBio sequencing was used to obtain complete high-quality reference chromosomal and plasmid sequences. Subsequently, sequences of randomly selected IncHI1 plasmids were obtained using MinION sequencing. For PacBio sequencing, genomic DNA was extracted using a NucleoSpin Microbial DNA kit (Macherey-Nagel, Germany). Libraries were prepared according to the microbial multiplexing protocol. Shearing was performed using g-tubes (Covaris, USA), and no size selection was done during library preparation. Sequencing was performed with the Sequel I platform (Pacific Biosciences, Menlo Park, CA, USA). For Oxford Nanopore Technologies (ONT) sequencing, the DNA was extracted using a Gentra Puregene Yeast/Bact. kit and a DNeasy blood and tissue kit (Qiagen, Hilden, Germany). Libraries were prepared using a 1D ligation barcoding kit (catalog no. SQK-LSK109 and EXP-NBD104; ONT, Oxford, UK) and were sequenced in R9.4.1 and Flongle flow cells with a MinION Mk1B (ONT).

Sequence data analysis. Raw data from short-read sequencing were adaptor and quality ($Q \leq 20$) trimmed using Trimmomatic (38), v 0.36. *De novo* assembly was performed using SPAdes (39), v3.13.1, with the “careful” option. For PacBio data, HGAP4 (40) in SMRT Link, v.6, was used to perform the assemblies with a minimum seed coverage of 30. Long reads from MinION were demultiplexed and converted from fast5 to fastq format using Guppy, v3.2.1 (ONT). The adaptors and low-quality ends ($Q \leq 8$) were trimmed using Porechop, v0.2.2 (<https://github.com/rwick/Porechop>) and BBDuk (<https://sourceforge.net/projects/bbmap/>), respectively. *De novo* hybrid assembly using short reads from Illumina and long reads from MinION was performed with Unicycler (41), v0.4.7. The complete chromosomal and plasmid sequences were annotated using RASTtk (42) and were manually curated according to GenBank in Geneious, v9.0.5.

Genomic characterization. The draft genome assemblies from WGS and Enterobase were analyzed for the presence of antibiotic resistance genes (ARGs), virulence genes, plasmid replicons, and serotypes. For this purpose, ABRicate (<https://github.com/tseemann/abricate>) was used with thresholds set to 90% identity and 95% query coverage against the databases ResFinder (43), VFDB (44), PlasmidFinder (45), and EcoH (46), respectively. Plasmid multilocus sequence typing (pMLST) was performed using pMLST by the Center for Genomic Epidemiology (45). MLST profiles were verified by mlst (<https://github.com/tseemann/mlst>), and the phylogroups were assessed using ClermonTyping (47).

Phylogenetic analysis. The phylogenetic relatedness of isolates was evaluated. The open reading frames were predicted from draft genome assemblies using Prokka (48), and GFF3 files were used for core genome alignment in Roary (49) with default settings (the percentage of isolates a gene must be in to be considered a core gene is 99%). The alignment was then used in RAxML (50) for calculating the phylogenetic tree under the GTR+GAMMA model supported by 1,000 bootstraps. The tree was visualized in iTOL, v4 (51), and GrapeTree (52). The nucleotide similarity between the isolates was determined by assessing the number of single nucleotide polymorphisms using snp-dists (<https://github.com/tseemann/snp-dists>) with the core genome alignment as an input.

Comparative genomics. Comparison of four high-quality annotated complete chromosomal *E. coli* ST1250 sequences obtained from PacBio sequencing with *E. coli* K-12 as a reference (GenBank accession no. U00096) was performed using progressiveMauve (53). *E. coli* K-12 was selected especially because of the lack of virulence genes and the high level of characterization its genetic content. Therefore, the comparison allowed us to see if there are virulence factors or any other genes that could offer an advantage for *E. coli* ST1250, since *E. coli* K-12 is a nonpathogenic strain. The complete annotated plasmid sequences were compared with respect to their plasmid replicon and plasmid ST using BLAST Ring Image Generator (54). The structure of the *fos* operon (nucleotides 61904 to 70800 of pEQ1 [GenBank accession no. KF362121]) was examined and compared to the sequence within pEQ1.

Data availability. The draft genome assemblies, the complete plasmid and chromosomal sequences, and the raw data from short-read sequencing have been deposited in GenBank and SRA, respectively, under BioProject number PRJNA638007. The complete nucleotide sequences of the plasmids have been deposited in GenBank under accession numbers MT586601 to MT586609.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 8.3 MB.

ACKNOWLEDGMENTS

We thank Katerina Rehakova, Iva Kutilova and Martina Masarikova for their excellent work in the laboratory. We thank Alois Cizek, the staff from the Equine Clinic of the University of Veterinary and Pharmaceutical Sciences Brno, and the terrain veterinarians for collecting and providing the samples or bacterial isolates. We are also grateful to Stefan Börjesson for his cooperation.

The study was funded mainly by the Czech Science Foundation (award 18-23532S to M.D.). P.S. received funds from the Internal Grant Agency of the University of Veterinary and Pharmaceutical Sciences Brno (award 204/2020/FVHE). J.H., I.B., and PacBio sequencing were funded by the Charles University Research Fund PROGRES (project Q39), by National Sustainability Program I (NPU I) grant LO1503, and by project CZ.02.1.01/0.0/0.0/16_019/0000787, "Fighting Infectious Diseases," provided by the Ministry of Education, Youth, and Sports of the Czech Republic. Isolates from the Czech Republic were collected and partially characterized within the project funded by the Internal Grant Agency of the University of Veterinary and Pharmaceutical Sciences Brno (grant 116/2015/FVL). MinION sequencing was funded by Horizon 2020 (award 773830), OH-EJP-H2020-JRP-AMR-2-ARDIG, and internal funding from Utrecht University.

We have no potential conflicts of interest to declare.

REFERENCES

1. Ewers C, Bethe A, Semmler T, Guenther S, Wieler LH. 2012. Extended-spectrum β -lactamase-producing and AmpC-producing *Escherichia coli* from livestock and companion animals, and their putative impact on public health: a global perspective. *Clin Microbiol Infect* 18:646–655. <https://doi.org/10.1111/j.1469-0691.2012.03850.x>.
2. El Salabi A, Walsh TR, Chouchani C. 2013. Extended spectrum β -lactamases, carbapenemases and mobile genetic elements responsible for antibiotics resistance in Gram-negative bacteria. *Crit Rev Microbiol* 39:113–122. <https://doi.org/10.3109/1040841X.2012.691870>.
3. McNulty C, Lecky DM, Xu-McCrae L, Nakiboneka-Ssenabulya D, Chung KT, Nichols T, Thomas HL, Thomas M, Alvarez-Buylla A, Turner K, Shabir S, Manzoor S, Smith S, Crocker L, Hawkey PM. 2018. CTX-M ESBL-producing *Enterobacteriaceae*: estimated prevalence in adults in England in 2014. *J Antimicrob Chemother* 73:1368–1388. <https://doi.org/10.1093/jac/dky007>.
4. Teklu DS, Negeri AA, Legese MH, Bedada TL, Woldemariam HK, Tullu KD. 2019. Extended-spectrum beta-lactamase production and multi-drug resistance among *Enterobacteriaceae* isolated in Addis Ababa, Ethiopia.

- Antimicrob Resist Infect Control 8:39. <https://doi.org/10.1186/s13756-019-0488-4>.
5. Dolejska M, Duskova E, Rybarikova J, Janoszowska D, Roubalova E, Dibdakova K, Maceckova G, Kohoutova L, Literak I, Smola J, Cizek A. 2011. Plasmids carrying *bla*_{CTX-M-1} and *qnr* genes in *Escherichia coli* isolates from an equine clinic and a horseback riding centre. *J Antimicrob Chemother* 66:757–764. <https://doi.org/10.1093/jac/dkq500>.
 6. Dolejska M, Villa L, Minoia M, Guardabassi L, Carattoli A. 2014. Complete sequences of IncHI1 plasmids carrying *bla*_{CTX-M-1} and *qnrS1* in equine *Escherichia coli* provide new insights into plasmid evolution. *J Antimicrob Chemother* 69:2388–2393. <https://doi.org/10.1093/jac/dku172>.
 7. Damborg P, Marskar P, Baptiste KE, Guardabassi L. 2012. Faecal shedding of CTX-M-producing *Escherichia coli* in horses receiving broad-spectrum antimicrobial prophylaxis after hospital admission. *Vet Microbiol* 154:298–304. <https://doi.org/10.1016/j.vetmic.2011.07.005>.
 8. Jakobsen L, Bortolaia V, Bielak E, Moodley A, Olsen SS, Hansen DS, Frimodt-Møller N, Guardabassi L, Hasman H. 2015. Limited similarity between plasmids encoding CTX-M-1 β -lactamase in *Escherichia coli* from humans, pigs, cattle, organic poultry layers and horses in Denmark. *J Glob Antimicrob Resist* 3:132–136. <https://doi.org/10.1016/j.jgar.2015.03.009>.
 9. Apostolakis I, Franz E, van Hoek AHAM, Florijn A, Veenman C, Sloet-van Oldruitenborgh-Oosterbaan MM, Dierikx C, van Duijkeren E. 2017. Occurrence and molecular characteristics of ESBL/AmpC-producing *Escherichia coli* in faecal samples from horses in an equine clinic. *J Antimicrob Chemother* 72:1915–1921. <https://doi.org/10.1093/jac/dkx072>.
 10. Hordijk J, Farmakioti E, Smit LAM, Duim B, Graveland H, Theelen MJ, Wagenaar JA. 2020. Faecal carriage of extended-spectrum- β -lactamase/AmpC-producing *Escherichia coli* in horses. *Appl Environ Microbiol* 86:e02590-19. <https://doi.org/10.1128/aem.02590-19>.
 11. Isgren CM, Edwards T, Pinchbeck GL, Winward E, Adams ER, Norton P, Timofte D, Maddox TW, Clegg PD, Williams NJ. 2019. Emergence of carriage of CTX-M-15 in faecal *Escherichia coli* in horses at an equine hospital in the UK: increasing prevalence over a decade (2008–2017). *BMC Vet Res* 15:268. <https://doi.org/10.1186/s12917-019-2011-9>.
 12. Ewers C, Bethel A, Stamm I, Grobber M, Kopp PA, Guerra B, Stubbe M, Doi Y, Zong Z, Kola A, Schaulfer K, Semmler T, Fruth A, Wieler LH, Guenther S. 2014. CTX-M-15-D-ST648 *Escherichia coli* from companion animals and horses: another pandemic clone combining multiresistance and extraintestinal virulence? *J Antimicrob Chemother* 69:1224–1230. <https://doi.org/10.1093/jac/dkt516>.
 13. Kaspar U, von Lützu K, Schlattmann A, Rösler U, Köck R, Becker K. 2019. Zoonotic multidrug-resistant microorganisms among non-hospitalized horses from Germany. *One Health* 7:100091. <https://doi.org/10.1016/j.onehlt.2019.100091>.
 14. Lupo A, Haenni M, Saras E, Gradin J, Madec JY, Börjesson S. 2018. Is *bla*_{CTX-M-1} riding the same plasmid among horses in Sweden and France? *Microb Drug Resist* 24:1580–1586. <https://doi.org/10.1089/mdr.2017.0412>.
 15. Sadikalay S, Reynaud Y, Guyomard-Rabenirina S, Falord M, Ducat C, Fabre L, Le Hello S, Talarmin A, Ferdinand S. 2018. High genetic diversity of extended-spectrum β -lactamases producing *Escherichia coli* in feces of horses. *Vet Microbiol* 219:117–122. <https://doi.org/10.1016/j.vetmic.2018.04.016>.
 16. de Lagarde M, Larrieu C, Praud K, Lallier N, Trotereau A, Sallé G, Fairbrother JM, Schouler C, Doublet B. 2020. Spread of multidrug resistance IncHI1 plasmids carrying ESBL gene *bla*_{CTX-M-1} and metabolism operon of prebiotic oligosaccharides in commensal *Escherichia coli* from healthy horses, France. *Int J Antimicrob Agents* 55:105936. <https://doi.org/10.1016/j.ijantimicag.2020.105936>.
 17. Schouler C, Taki A, Chouikha I, Moulin-Schouleur M, Gilot P. 2009. A genomic island of an extraintestinal pathogenic *Escherichia coli* strain enables the metabolism of fructooligosaccharides, which improves intestinal colonization. *J Bacteriol* 191:388–393. <https://doi.org/10.1128/JB.01052-08>.
 18. Respondek F, Myers K, Smith TL, Wagner A, Geor RJ. 2011. Dietary supplementation with short-chain fructo-oligosaccharides improves insulin sensitivity in obese horses. *J Anim Sci* 89:77–83. <https://doi.org/10.2527/jas.2010-3108>.
 19. Sonnenborn U, Schulze J. 2009. The non-pathogenic *Escherichia coli* strain Nissle 1917 — features of a versatile probiotic. *Microb Ecol Health Dis* 21:122–158. <https://doi.org/10.3109/08910600903444267>.
 20. Qi B, Han M. 2018. Microbial siderophore enterobactin promotes mitochondrial iron uptake and development of the host via interaction with ATP synthase. *Cell* 175:571–582.e11. <https://doi.org/10.1016/j.cell.2018.07.032>.
 21. Girón JA, Torres AG, Freer E, Kaper JB. 2002. The flagella of enteropathogenic *Escherichia coli* mediate adherence to epithelial cells. *Mol Microbiol* 44:361–379. <https://doi.org/10.1046/j.1365-2958.2002.02899.x>.
 22. Qin X, Hu F, Wu S, Ye X, Zhu D, Zhang Y, Wang M. 2013. Comparison of adhesin genes and antimicrobial susceptibilities between uropathogenic and intestinal commensal *Escherichia coli* strains. *PLoS One* 8:e61169. <https://doi.org/10.1371/journal.pone.0061169>.
 23. Talmi-Frank D, Altboum Z, Solomonov I, Udi Y, Jaitin DA, Klepfish M, David E, Zhuravlev A, Keren-Shaul H, Winter DR, Gat-Viks I, Mandelboim M, Ziv T, Amit I, Sagi I. 2016. Extracellular matrix proteolysis by MT1-MMP contributes to influenza-related tissue damage and mortality. *Cell Host Microbe* 20:458–470. <https://doi.org/10.1016/j.chom.2016.09.005>.
 24. Francetic O, Pugsley AP. 1996. The cryptic general secretory pathway (*gsp*) operon of *Escherichia coli* K-12 encodes functional proteins. *J Bacteriol* 178:3544–3549. <https://doi.org/10.1128/jb.178.12.3544-3549.1996>.
 25. Francetic O, Belin D, Badaut C, Pugsley AP. 2000. Expression of the endogenous type II secretion pathway in *Escherichia coli* leads to chitinase secretion. *EMBO J* 19:6697–6703. <https://doi.org/10.1093/emboj/19.24.6697>.
 26. Bébian M, Kirsch J, Méjean V, Verméglio A. 2002. Involvement of a putative molybdenum enzyme in the reduction of selenate by *Escherichia coli*. *Microbiology (Reading)* 148:3865–3872. <https://doi.org/10.1099/00221287-148-12-3865>.
 27. Minazzato G, Gasparrini M, Amici A, Cianci M, Mazzola F, Orsomando G, Sorci L, Raffaelli N. 2020. Functional characterization of COG1713 (YqeK) as a novel diadenosine tetraphosphate hydrolase family. *J Bacteriol* 202:e00053-20. <https://doi.org/10.1128/jb.00053-20>.
 28. Frederix M, Hütter K, Leu J, Bath TS, Turner WJ, Rüegg TL, Blanch HW, Simmons BA, Adams PD, Keasling JD, Thelen MP, Dunlop MJ, Petzold CJ, Mukhopadhyay A. 2014. Development of a native *Escherichia coli* induction system for ionic liquid tolerance. *PLoS One* 9:e101115. <https://doi.org/10.1371/journal.pone.0101115>.
 29. Jenkins LS, Nunn WD. 1987. Regulation of the *ato* operon by the *atoC* gene in *Escherichia coli*. *J Bacteriol* 169:2096–2102. <https://doi.org/10.1128/jb.169.5.2096-2102.1987>.
 30. Seeger C, Poulsen C, Dandanell G. 1995. Identification and characterization of genes (*xapA*, *xapB*, and *xapR*) involved in xanthosine catabolism in *Escherichia coli*. *J Bacteriol* 177:5506–5516. <https://doi.org/10.1128/jb.177.19.5506-5516.1995>.
 31. Koga M, Otsuka Y, Lemire S, Yonesaki T. 2011. *Escherichia coli* *rmlA* and *rmlB* compose a novel toxin-antitoxin system. *Genetics* 187:123–130. <https://doi.org/10.1534/genetics.110.121798>.
 32. Cain AK, Hall RM. 2013. Evolution of IncHI1 plasmids: two distinct lineages. *Plasmid* 70:201–208. <https://doi.org/10.1016/j.plasmid.2013.03.005>.
 33. Smith H, Bossers A, Harders F, Wu G, Woodford N, Schwarz S, Guerra B, Rodriguez I, van Essen-Zandbergen A, Brouwer M, Mevius D. 2015. Characterization of epidemic IncI1-y plasmids harboring Ambler class A and C genes in *Escherichia coli* and *Salmonella enterica* from animals and humans. *Antimicrob Agents Chemother* 59:5357–5365. <https://doi.org/10.1128/AAC.05006-14>.
 34. Wang Y, Tong MK, Chow KH, Cheng VCC, Tse CWS, Wu AKL, Lai RWM, Luk WK, Tsang DNC, Ho PL. 2018. Occurrence of highly conjugative IncX3 epidemic plasmid carrying *bla*_{NDM-5} in *Enterobacteriaceae* isolates in geographically widespread areas. *Front Microbiol* 9:2272. <https://doi.org/10.3389/fmicb.2018.02272>.
 35. Ho PL, Wang Y, Liu MCJ, Lai ELY, Law PYT, Cao H, Chow KH. 2018. IncX3 epidemic plasmid carrying *bla*_{NDM-5} in *Escherichia coli* from swine in multiple geographic areas in China. *Antimicrob Agents Chemother* 62:e00295-17. <https://doi.org/10.1128/AAC.02295-17>.
 36. Chouikha I, Germon P, Brée A, Gilot P, Moulin-Schouleur M, Schouler C. 2006. A *selC*-associated genomic island of the extraintestinal avian pathogenic *Escherichia coli* strain BEN2908 is involved in carbohydrate uptake and virulence. *J Bacteriol* 188:977–987. <https://doi.org/10.1128/JB.188.3.977-987.2006>.
 37. CLSI. 2018. Performance standards for antimicrobial susceptibility testing; twenty-eighth informational supplement. CLSI document M100-S28. Clinical and Laboratory Standards Institute, Wayne, PA.
 38. Bolger AM, Marc L, Bjoern U. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30:2114–2120. <https://doi.org/10.1093/bioinformatics/btu170>.
 39. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Pribelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol* 19:455–477. <https://doi.org/10.1089/cmb.2012.0021>.

40. Chin CS, Alexander DH, Marks P, Klammer AA, Drake J, Heiner C, Clum A, Copeland A, Huddleston J, Eichler EE, Turner SW, Korlach J. 2013. Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data. *Nat Methods* 10:563–569. <https://doi.org/10.1038/nmeth.2474>.
41. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. *PLoS Comput Biol* 13:e1005595. <https://doi.org/10.1371/journal.pcbi.1005595>.
42. Brettin T, Davis JJ, Disz T, Edwards RA, Gerdes S, Olsen GJ, Olson R, Overbeek R, Parrello B, Pusch GD, Shukla M, Thomason JA, Stevens R, Vonstein V, Wattam AR, Xia F. 2015. RASTtk: a modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. *Sci Rep* 5:8365. <https://doi.org/10.1038/srep08365>.
43. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother* 67:2640–2644. <https://doi.org/10.1093/jac/dks261>.
44. Liu B, Zheng D, Jin Q, Chen L, Yang J. 2019. VFDB 2019: a comparative pathogenomic platform with an interactive web interface. *Nucleic Acids Res* 47:D687–D692. <https://doi.org/10.1093/nar/gky1080>.
45. Carattoli A, Zankari E, García-Fernández A, Larsen MV, Lund O, Villa L, Aarestrup FM, Hasman H. 2014. *In silico* detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895–3903. <https://doi.org/10.1128/AAC.02412-14>.
46. Ingle DJ, Valcanis M, Kuzevski A, Tauschek M, Inouye M, Stinear T, Levine MM, Robins-Browne RM, Holt KE. 2015. EcoH: *in silico* serotyping of *E. coli* from short read data. *BioRxiv*:e032151. <https://doi.org/10.1101/032151>.
47. Beghain J, Bridier-Nahmias A, Le Nagard H, Denamur E, Clermont O. 2018. ClermonTyping: an easy-to-use and accurate *in silico* method for *Escherichia* genus strain phylotyping. *Microb Genomics* 4:7. <https://doi.org/10.1099/mgen.0.000192>.
48. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30:2068–2069. <https://doi.org/10.1093/bioinformatics/btu153>.
49. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, Fookes M, Falush D, Keane JA, Parkhill J. 2015. Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics* 31:3691–3693. <https://doi.org/10.1093/bioinformatics/btv421>.
50. Stamatakis A. 2006. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. *Bioinformatics* 22:2688–2690. <https://doi.org/10.1093/bioinformatics/btl446>.
51. Letunic I, Bork P. 2019. Interactive Tree Of Life (iTOL) v4: recent updates and new developments. *Nucleic Acids Res* 47:W256–W259. <https://doi.org/10.1093/nar/gkz239>.
52. Zhou Z, Alikhan NF, Sergeant MJ, Luhmann N, Vaz C, Francisco AP, Carriço JA, Achtman M. 2018. Grapetree: visualization of core genomic relationships among 100,000 bacterial pathogens. *Genome Res* 28:1395–1404. <https://doi.org/10.1101/gr.232397.117>.
53. Darling AE, Mau B, Perna NT. 2010. progressiveMauve: multiple genome alignment with gene gain, loss and rearrangement. *PLoS One* 5:e11147. <https://doi.org/10.1371/journal.pone.0011147>.
54. Alikhan NF, Petty NK, Ben Zakour NL, Beatson SA. 2011. BLAST Ring Image Generator (BRIG): simple prokaryote genome comparisons. *BMC Genomics* 12:402. <https://doi.org/10.1186/1471-2164-12-402>.